CRISPR Therapeutics (NASDAQ:CRSP) gains visibility as biotechnology activity aligns with broader movements across the Nasdaq ...
A one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and reduced triglycerides by ...
Two years ago, the UK became the first country to approve Casgevy, a Crispr-based therapy for the blood disorders sickle cell disease and β-thalassaemia. This year saw the world’s first personalised ...
Promising results from a small clinical trial highlight a growing interest in designing gene-editing treatments for common illnesses. So far, only 15 people have received the treatment. But, if all ...
CHICAGO, Nov 8 (Reuters) - A single infusion of CRISPR Therapeutics' (CRSP.BN), opens new tab experimental gene therapy was safe and reduced levels of harmful LDL cholesterol and triglycerides by half ...
A single infusion of an experimental gene-editing drug appears safe and effective for cutting cholesterol, possibly for life, according to a small early study released Saturday. The study, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback